MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia

Single-arm, prospective, open-label feasibility study evaluating the technical and operational feasibility of manufacturing autologous CD19-directed CAR-T cells (MB-CART19.1) at the point of care for the treatment of relapsed or refractory B-ALL in pediatric and adult patients.

Trial Details

NCT ID
NCT07371403
Phase
NA
Sponsor
King Hussein Cancer Center
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • MB-CART19.1
Locations (sample)
  • Amman, Jordan|31.95522,35.94503

Key Eligibility Criteria

  • Age ≥ 1 year as long as if deemed fit by treating investigator
  • CD19 expression must be detected (≥20%) on the malignant cells by flow cytometry.
  • Patients with relapsed or refractory disease with \>5% blasts in the bone marrow after at least one frontline and one salvage chemotherapy regimen.…
  • Patients who have relapsed post alloSCT at least 100 days post-transplant, with no evidence of active graft vs host disease, and no longer taking i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →